Evolent Health, Inc. Earnings Recaps
Q2 2026
Aug 11, 2026
Evolent’s shares surged 28.2% following an earnings report that beat expectations on revenue growth, early positive performance from new contracts, and accelerating AI-driven efficiency gains.
Key takeaways
- Q2 revenue rose 31% sequentially to $653 million, driven by new and expanded customer partnerships.
- Adjusted EBITDA grew 27% quarter-over-quarter to $28 million, supported by higher volumes and operational improvements.
- Medical Expense Ratio (MER) increased to 95% from 93% due to the May 2026 launch of the Highmark contract.
- Strong contract renewal momentum, including key agreements with Aetna, Highmark, and a regional Blue Cross plan, providing visibility into 2027.
- AI-powered authorization approvals reached 75%, up from 55%, streamlining claims processing and reducing administrative burdens, signaling meaningful cost and productivity improvements.